Amy L. Cox

Hepatic and glucagon-like peptide-1–mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors

Kyle W. Sloop, Julia X.C. Cao, Angela M. Siesky et al. · Journal of Clinical Investigation · 2004 · 215 citations · Full text

Medicine, Endocrinology, Pharmacology +17

Novel Small Molecule Glucagon-Like Peptide-1 Receptor Agonist Stimulates Insulin Secretion in Rodents and From Human Islets

Kyle W. Sloop, Francis S. Willard, Martin Brenner et al. · Diabetes · 2010 · 140 citations · Full text

Medicine, Endocrinology, Pharmacology +17

Reduction of Hepatic and Adipose Tissue Glucocorticoid Receptor Expression With Antisense Oligonucleotides Improves Hyperglycemia and Hyperlipidemia in Diabetic Rodents Without Causing Systemic Glucocorticoid Antagonism

Lynnetta M. Watts, Vara Prasad Manchem, Thomas A. Leedom et al. · Diabetes · 2005 · 137 citations · Full text

Life Sciences, Endocrinology, Pharmacology +17

The dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: A p <scp>ost hoc</scp> analysis

Jonathan M. Wilson, Yanzhu Lin, Mengdie Luo et al. · Diabetes Obesity and Metabolism · 2021 · 128 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Hybrid insulin cocrystals for controlled release delivery

Mark L. Brader, Muppalla Sukumar, Allen H. Pekar et al. · Nature Biotechnology · 2002 · 91 citations

Pharmacy, Molecular Pharmaceutics, Pharmaceutics +10